Blog
RSS FeedPosted by Michael Wonder on 16 May 2024
It is time to reconsider the 3% discount rate
15 May 2024 - Health technology assessment guidance often recommends a 3% real annual discount rate, the appropriateness of which ...
Posted by Michael Wonder on 18 May 2024
FDA withdraws accelerated approval to infigratinib for metastatic cholangiocarcinoma
16 May 2024 - Today, the FDA announced the final withdrawal of the approval of infigratinib (Truseltiq) for previously treated, ...
Posted by Michael Wonder on 17 May 2024
HLB shares plummet following FDA rejection of liver cancer drug approval
17 May 2024 - HLB revealed that its US subsidiary, Elevar Therapeutics, and their Chinese partner, Jiangsu Hengrui Pharmaceuticals, received ...
Posted by Michael Wonder on 17 May 2024
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A
17 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 17 May 2024
Chemists to lose dollar discount option as government bows to Pharmacy Guild pressure
16 May 2024 - Chemist Warehouse will be stripped of its ability to give its customers $1 off their medicines, ...
Posted by Michael Wonder on 17 May 2024
Health Canada approves Saladax’s 5-fluorouracil chemotherapy therapeutic drug monitoring test
14 May 2024 - Saladax Biomedical is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil (My5-FU) Assay for sale ...
Posted by Michael Wonder on 16 May 2024
Nuvalent receives US FDA breakthrough therapy designation for NVL-655
16 May 2024 - Nuvalent today announced that the US FDA has granted breakthrough therapy designation to NVL-655 for the ...
Posted by Michael Wonder on 16 May 2024
Delegation from Taiwan visits IQWiG
15 May 2024 - At the end of April 2024, Mao-Ting Sheen visited the Institute for Quality and Efficiency in Healthcare ...
Posted by Michael Wonder on 16 May 2024
As childhood asthma worsens, insurers restrict access to an essential medication
16 May 2024 - As paediatricians who take care of children in the inpatient, emergency, and primary care settings, we ...
Posted by Michael Wonder on 16 May 2024
FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer
16 May 2024 - Today, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive stage small cell lung ...
Posted by Michael Wonder on 16 May 2024
Axogen initiates rolling submission of biologics license application to US FDA for Avance Nerve Graft
16 May 2024 - Axogen is pleased to announce that it has initiated the rolling submission process with the US FDA ...
Posted by Michael Wonder on 16 May 2024
Tisagenlecleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia
15 May 2024 - NICE has published final evidence-based recommendations on the use of tisagenlecleucel (Kymriah) for the treatment of ...
Posted by Michael Wonder on 16 May 2024
Acceptability of using real world data to estimate relative treatment effects in health technology assessments: barriers and future steps
15 May 2024 - Evidence about the comparative effects of new treatments is typically collected in randomised controlled trials (RCTs). In ...
Posted by Michael Wonder on 16 May 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (final guidance)
15 May 2024 - NICE has published final evidence-based recommendations on the use of selinexor (Nexpovio) in combination with bortezomib ...
Posted by Michael Wonder on 15 May 2024
FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma
15 May 2024 - Today, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics) for adults with relapsed ...